MedTrace Logo

INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer

NCT00008255 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Doctors can diagnose lung cancer by collecting mucus coughed up from the lungs and examining it under a microscope to look for cancer cells. Breathing in INS316 may make it easier for patients to cough up mucus.

PURPOSE: Randomized phase II trial to study the effectiveness of INS316 in helping to diagnose lung cancer.

Conditions

Interventions

DRUG

INS316

OTHER

sputum cytology

Sponsors & Collaborators

Principal Investigators

  • Robert J. Korst, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
DIAGNOSTIC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-08-31
Completion
2004-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00008255 on ClinicalTrials.gov